{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:45:27Z","timestamp":1698489927914},"reference-count":38,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T00:00:00Z","timestamp":1233705600000},"content-version":"vor","delay-in-days":4967,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[1995,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared the efficacy and tolerability of is\u2010radipine (ISR) and fosinopril (FOS) once\u2010a\u2010day administration in 17 outpatients, 9 men and 8 women, aged 35\u201365 years (mean \u00b1 SD= 58 \u00b1 10 years), affected by mild to moderate primary systemic hypertension. The patients were given single\u2010blind placebo for 2 weeks and thereafter, in double\u2010blind, randomized, crossover sequence, ISR (5 mg) and FOS (20 mg), both for 4 weeks. At the end of each period, patients underwent 24\u2010h noninvasive blood pressure (BP) monitoring by means of an A&amp;D TM 2420 Monitor Model 7, with readings taken every 10 min during the day (from 7 A.M. to 11 P.M.), and every 20 min during the night (from 11 P.M. to 7 A.M.). Similarly, BP load (BPL) as percentage of systolic and diastolic BP reading &gt; 140 and &gt; 90 mmHg was investigated. Both ISR and FOS induced a highly significant (p&lt;0.0001) decrease in BP from 158\/96 \u00b1 7\/6 mmHg to 133\/86 \u00b1 6\/6 and to 132\/83 \u00b1 10\/7 mmHg, respectively. Mean BP decreased from 117 \u00b1 6 mmHg to 102 \u00b1 6 mmHg (ISR) (p&lt;0.0001) and to 99 \u00b1 8 mmHg (FOS) (p&lt;0.0001). Both ISR and FOS significantly (p&lt;0.0001) reduced systolic BPL from 78 \u00b1 16% to 44 \u00b1 13% and 28 \u00b1 12%, respectively, and diastolic BPL from 70 \u00b1 15% to 40 \u00b1 13% (p&lt;0.0001) and 35 \u00b1 13% (p&lt;0.0001), respectively. A significant difference between the two drugs in systolic (p&lt;0.0002) BPL was observed. No significant differences in heart rate were noted. No unexpected adverse effects were observed in any patient under either therapy. Both ISR and FOS resulted in very effective decrease in BP; however, FOS proved to be significantly more effective than ISR.<\/jats:p>","DOI":"10.1002\/clc.4960180708","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T07:00:18Z","timestamp":1233730818000},"page":"401-407","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of antihypertensive effects of once\u2010a\u2010day isradipine and fosinopril: A double\u2010blind crossover study by means of ambulatory blood pressure monitoring"],"prefix":"10.1002","volume":"18","author":[{"given":"Francesco","family":"Perticone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Marcantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosima","family":"Cloro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-02720-2"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90955-7"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.246"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.175"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(88)90185-4"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/00005344-198904000-00010","article-title":"Efficacy and safety of isradipine in hypertension","volume":"13","author":"Shepherd AM","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199106183-00005"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199200001-00009"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198906000-00005"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199200001-00008"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/ajh\/4.2.175S","article-title":"Platelet\u2010activating effect of low\u2010density lipoprotein and its reversal by isradipine","volume":"4","author":"Fetkovska N","year":"1991","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_13_2","first-page":"581","article-title":"Isradipine long\u2010term administration is very effective in lowering serum cholesterol in hypertensive patients (abstr)","volume":"12","author":"Perticone F","year":"1993","journal-title":"J Am Coll Nut"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198600101-00015"},{"key":"e_1_2_1_15_2","first-page":"152S","article-title":"Disposition of fosinopril sodium (F) in bile duct\u2010cannulated (BDC) rats (abstr)","volume":"3","author":"Dean AV","year":"1986","journal-title":"Pharmacol Res"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03275.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.54"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.1991.03460110080028","article-title":"Age\u2010related characteristics of ambulatory blood pressure load and mean blood pressure in normotensive subjects","volume":"265","author":"Zachariah PK","year":"1991","journal-title":"J Am Med Assoc"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/13.suppl_G.43"},{"key":"e_1_2_1_20_2","first-page":"77","article-title":"Ambulatory blood pressure monitoring: Validation of the TM\u20102420 according to the AAMI recommendations","volume":"5","author":"Clark S","year":"1991","journal-title":"J Hum Hypertens"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/ajh\/4.11.890","article-title":"A multicenter evaluation of the A&D TM\u20102420 ambulatory blood pressure recorder","volume":"4","author":"White WB","year":"1991","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"135S","DOI":"10.1093\/ajh\/4.2.135S","article-title":"Isradipine: Overall clinical experience in hypertension in the United States","volume":"4","author":"Miller H","year":"1991","journal-title":"Am J Hypertens"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199200001-00010"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90944-Z"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199200001-00002"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)90279-8"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.8.2.230"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.75.1.131"},{"issue":"5","key":"e_1_2_1_29_2","first-page":"S9","article-title":"Circadian variation in blood pressure: Considerations for therapy","volume":"67","author":"Raftery EB","year":"1991","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1159\/000175044"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.20.4.473"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92998-7"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91027-7"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.17.5.636"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(91)90852-Z"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92703-4"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80057-1"},{"issue":"3","key":"e_1_2_1_38_2","first-page":"S47","article-title":"Metabolic disturbances and antihypertensive therapy","volume":"9","author":"Mancini M","year":"1991","journal-title":"J Hypertens"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.58.2.305"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.4960180708","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.4960180708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T20:19:53Z","timestamp":1698265193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.4960180708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,7]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1995,7]]}},"alternative-id":["10.1002\/clc.4960180708"],"URL":"https:\/\/doi.org\/10.1002\/clc.4960180708","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,7]]}}}